Experimental vaccine aims to boost immune attack on myeloma cells
NCT ID NCT02334865
First seen May 15, 2026 · Last updated May 15, 2026
Summary
This early-stage study tests whether a vaccine made from a protein called survivin can safely help the immune system fight multiple myeloma. About 18 adults whose myeloma has partially responded to initial treatment will receive the vaccine along with standard lenalidomide maintenance therapy. The main goal is to check for side effects and see if the vaccine triggers an immune response against cancer cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
University of Rochester Medical Center
Rochester, New York, 14642, United States
Conditions
Explore the condition pages connected to this study.